Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant

Emma Birnie; Jason J Biemond; Brent Appelman; Godelieve J de Bree; Marcel Jonges; Matthijs R A Welkers; W Joost Wiersinga

doi:10.1001/jama.2022.13854

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant

JAMA. 2022 Sep 20;328(11):1104-1107. doi: 10.1001/jama.2022.13854.

Authors

Emma Birnie¹, Jason J Biemond¹, Brent Appelman¹, Godelieve J de Bree², Marcel Jonges³, Matthijs R A Welkers³, W Joost Wiersinga¹

Affiliations

¹ Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
² Division of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
³ Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

Abstract

This study investigates whether resistance-associated mutations develop after treatment with sotrovimab in high-risk patients infected with the SARS-CoV-2 Omicron variant.

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Antibodies, Monoclonal, Humanized* / pharmacology
Antibodies, Monoclonal, Humanized* / therapeutic use
Antibodies, Neutralizing* / adverse effects
Antibodies, Neutralizing* / pharmacology
Antibodies, Neutralizing* / therapeutic use
COVID-19 Drug Treatment*
COVID-19* / genetics
COVID-19* / virology
Drug Resistance, Viral* / drug effects
Drug Resistance, Viral* / genetics
Humans
Mutation
SARS-CoV-2* / drug effects
SARS-CoV-2* / genetics

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
sotrovimab

Supplementary concepts

SARS-CoV-2 variants